ACUTE MYELOID LEUKEMIA- A RETROSPECTIVE CLAIMS ANALYSIS OF RESOURCE UTILIZATION AND EXPENDITURES FOR DE NOVO PATIENTS FROM FIRST-LINE INDUCTION TO REMISSION AND RELAPSE
Author(s)
Irish W1, Ryan MP2, Gache LM2, Gunnarsson C2, Bell T3, Shapiro M3
1CTI Clinical Trial and Consulting Services, Raleigh, NC, USA, 2CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, 3Pfizer, Inc., New York, NY, USA
OBJECTIVES: The objective of this study was to estimate resource utilization and expenditures for AML patients in a real world claims database. METHODS: All AML patients with ICD-9 diagnosis code of 205.00 and a record of hospitalization within 14 days after their initial diagnosis between 1/1/2009 - 1/31/2015 were identified in the MarketScan claims databases. Patients had a minimum of two AML diagnosis codes and ≥6 months of enrollment prior to first diagnosis. Patients with a record of first line induction to a record of remission were followed. A subset had a record of a second treatment period defined as time from relapse to remission. Patient demographics, AML risk factors, and comorbidities, were recorded. Descriptive analysis of utilization and expenditures (in 2014 dollars) were reported for each cohort. RESULTS:
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Value in Health, Vol. 19, No. 3 (May 2016)
Code
PCN181
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology